Background: Anti-phospholipase A2 receptor (anti-PLA 2 R) is a promising biomarker for diagnosis, activity evaluation, therapy monitoring, and prognostic estimation of primary membranous neuropathy (pMN). Difference in methodology may be one cause of the discrepancy in anti-PLA 2 R-positive percentages in reported studies. In this study, we evaluated the determination consistency of anti-PLA 2 R using indirect immunofluorescence assay (IIF) and enzyme-linked immunosorbent assay (ELISA).
Membranous nephropathy (MN) is a common cause of nephritic syndrome in adults. 1 Primary membranous nephropathy (pMN), as an organ-specific autoimmune disease, accounts for approximately 80% of all MN cases, whereas secondary MN (sMN) explains the other 20%. Hospital of Gaoyangxian, Gaoyangxian, China; 4 Department of Blood Transfusion, Hebei Provincial Chest Hospital, Shijiazhuang, China.
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The differential diagnosis of pMN and sMN is largely based on exclusion of secondary causes such as malignant neoplasms, systemic lupus erythematosus (SLE), bacterial infection, and drug intoxication. 3, 4 Patients with pMN need to undergo immunosuppressive therapy, whereas sMN therapy is mainly aimed at the treatment of underlying disease.
The etiology of pMN was obscure until the landmark study by Beck et al 5 in 2009, the results of which demonstrated that M-type phospholipase A2 receptor (PLA 2 R), a transmembrane glycoprotein expressed on podocytes, was the main target antigen of the autoantibody in pMN. Lately, thrombospondin type-1 domain-containing 7A (THSD7A) was identified as the second target antigen, with a prevalence of 2% to 3% among patients with MN. 6, 7 Circulating anti-PLA 2 R is presently considered to be a promising protential serological diagnostic biomarker of pMN. 7, 8 The results of 2 studies 9, 10 indicate that 52% to 82% of patients with pMN had circulating anti-PLA 2 R in accordance with geographic regions. Moreover, anti-PLA 2 R is now expected to be a biomarker of pMN activity, a cue for immunosuppressive therapy monitoring, and a tool for predicting disease outcomes. [11] [12] [13] Western blot (WB), enzyme-linked immunosorbent assay (ELISA), and indirect immunofluorescence assay (IIF) are the 3 main methods of detecting anti-PLA 2 R; the difference in methodology may be a cause for the discrepancy in anti-PLA 2 R-positive percentages in reported studies. WB is labor-intensive and unsuitable for the evaluation of large numbers of specimens. To date, ELISA and IIF are widely used assays for detecting anti-PLA 2 R in clinical laboratories.
The purpose of the current study was to evaluate the determination consistency of anti-PLA 2 R by using commercially available ELISA and IIF kits.
Materials and Methods

Patients and Specimens
This study was carried out at The Second Hospital of Hebei Medical University in Shijiazhuang, China from April 2016 through June 2017. A total of 147 patients with MN, including 113 patients with pMN and 34 with sMN, were consecutively enrolled. PMN was diagnosed in patients with biopsy-proven MN but without laboratory or clinical signs of known underlying diseases or suspected drug exposure. No immunosuppressive therapy for patients with pMN was allowed before inclusion. Patients were diagnosed with sMN according to renal biopsy findings of MN and secondary causes. Among the 34 patients with sMN, the underlying diseases included SLE (n = 7), autoimmune thyroid disease (n = 10), rheumatoid arthritis (n = 1), hepatitis B virus infection (n = 9), hepatitis C virus infection (n = 1), gastric cancer (n = 3), multiple myeloma (n = 1) and intoxication with nonsteroidal anti-inflammatory drugs (n = 2). Also, 53 serum specimens from healthy volunteers were included as healthy control specimens. Serum was isolated within 1 hour after venous blood collection. From each blood specimen, 500 μL of serum was separated and stored at −70°C until the measurement of anti-PLA 2 R. Biochemistry parameters, including blood urea nitrogen (BUN), serum creatinine, total protein (TP), albumin, cholesterol, triglycerides, and 24-hour urine protein, were determined within 2 hours after specimen collection. The study was approved by the Ethics Committee of the Second Hospital of Hebei Medical University (approval no. 2016248), and written informed consent was obtained from all patients.
Determination of Biochemistry Parameters
Serum analysis for BUN, creatinine, TP, albumin, cholesterol, triglycerides, and 24-hour urine protein was performed via the Cobas 6000 automatic biochemistry analyzer (F. Hoffman-La Roche Ltd), using corresponding reagents produced by the manufacturer. Reference ranges of various parameters were applied according to the protocols of the manufacturer.
Anti-PLA 2 R Determination via IIF
We performed circulating anti-PLA 2 R testing using a recombinant cell-based IIF test (EUROIMMUN AG) according to the manufacturer-provided protocol. The test used a 5-mm biochip mosaic with a composite substrate containing formalin-fixed human embryonic kidney 293 (HEK293) cells, which were transfected with full-length complementary DNA, encoding PLA 2 R and nontransfected HEK 293 cells as a negative control. Fluorescein isothiocyanate (FITC)-labeled goat antihuman immunoglobulin (Ig)G conjugate was used as the revealing reagent. We diluted serum specimens 1:10 in specimen buffer (0.05% Tween 20, 1% casein in PBS) and then applied 30 μL of diluted serum to the reaction fields, followed by incubation at room temperature for 30 minutes. After rinsing slides with specimen buffer and immersing them in specimen buffer for 5 minutes or more, 25 μL of revealing reagent was added, and the resulting product was incubated for 30 minutes. Immunostain was evaluated using a fluorescence microscope (EUROStar III plus, EUROIMMUN AG), with excitation of 460 to 490 nm. Specific fluorescence in the cytoplasm of transfected cells but not in negative control cells at a dilution of 1:10 or higher was considered to indicate a positive result. Further dilution of 1:100, 1:1000, or 1:10000 was performed for specimen with positive results to determine the final titer of anti-PLA 2 R.
Anti-PLA 2 R Determination via ELISA
We used a commercial quantitative ELISA assay (EUROIMMUN AG) for the IgG-specific isotype of anti-PLA 2 R, according to manufacturer instructions. In brief, serum specimens were diluted 1:100 in PBS-Tween. Then, 100-μL diluted specimens; calibrators with anti-PLA 2 R concentration of 2, 100, 500, and 1500 RU per mL; and controls with negative and positive results were added to microplate wells and incubated for 30 minutes at room temperature, followed by 3 washing steps. Anti-human-IgG horseradish peroxidase (HRP) conjugate diluted 1:1000 in specimen buffer was transferred to every microplate well for another 30 minutes of incubation, followed by 3 washing steps and the addition of 3,3′,5,5′-tetramethylbenzidine (TMB) substrate for 15 minutes incubation subsequently. Optical density at 450 nm was read using a microplate photometer (Multiskan FC, ThermoFisher Scientific Inc). We applied a cutoff value of 20 RU per mL for diagnosis according to manufacturer protocol.
Statistical Analysis
Data are presented as mean (SD) for normally distributed values or median with interquartile range (IQR) for non-normally distributed values; qualitative variables were described as numbers and percentages. We performed statistical comparisons among 3 groups using 1-way analysis of variance (ANOVA) and Scheffe posthoc tests for values with normal distributions or Kruskal-Wallis H tests for data with non-normal distributions. We used χ 2 testing to compare differences between qualitative variables. We used Spearman correlation analyses to assess the correlations between portions and Cohen kappa values to analyze the agreement between the 2 studied immunoassays. To assess the diagnostic performance of biomarkers, we conducted receiver operating characteristic (ROC) curve analysis and compared the areas under the curves (AUCs). All tests were 2-sided; P values less than .05 were considered statistically significant. We performed statistical analyses using SPSS statistical software, version 22.0 (IBM).
Results
Baseline Clinical Characteristics and Laboratory Findings
The baseline clinical characteristics of and laboratory findings for the study and control populations are shown in Table 1 . Overall, pMN was predominant in men (56.6%) and sMN was predominant in women (52.9%). Healthy control individuals comprised 34 men and 19 women, with mean (SD) age of 53.5 (16.5) years. There was no significant difference in age and sex distributions (x 2 = 0.483, P = .29).
TP and albumin levels in patients with sMN were found to be higher than those levels in the pMN group and lower than in controls. Patients with sMN had lower cholesterol and 24-hour urine protein levels than patients with pMN and higher levels than in controls. Patients with pMN and sMN had higher triglyceride levels and lower creatinine levels than controls ( Figure 2 ).
Discussion
Since the study of anti-PLA 2 R by Beck et al 5 in 2009, an increasing amount of study results have verified that anti-PLA 2 R plays a pivotal role in the pathogenesis of pMN, although the exact mechanism is still under investigation. A widely accepted viewpoint is that in patients with pMN, subepithelial deposition occurs in situ by the binding of circulating anti-PLA 2 R on podocytes, leading to activation of complement and a cascade of events subsequent to nephritic syndrome. 3 Moreover, it is now assumed that conformational change of PLA 2 R induced by molecular mimicry of exogenous antigens or by unknown causes could participate in the etiology of pMN. 1 Consistent with the findings of previous studies, [11] [12] [13] when laboratory values from patients with pMN and those with sMN were compared in the present study, the anti-PLA 2 R levels were significantly higher in patients with pMN. Although the exact mechanisms and the role of PLA 2 R in pathogenesis of pMN are currently still unknown, 7 our data strengthen the role of PLA 2 R as a target antigen in pMN. Through ROC analysis, we discovered that the AUC of anti-PLA 2 R determined via ELISA or IIF was higher than that of TP, albumin, cholesterol, triglycerides, or 24-hour urine protein. Therefore, these data suggested that circulating anti-PLA 2 R can serve as an alternative diagnostic biomarker for pMN.
However, the reported prevalence of anti-PLA 2 R in patients with pMN varied from 52% to 82%. The heterogeneity among studies probably implied that some potential factors might impact the diagnostic accuracy of anti-PLA 2 R assays. Initially, researchers believed that the interval between the time of diagnosis and blood collection might induce this inconsistency. In the study by Svobodava et al, 10 the sensitivity of anti-PLA 2 R was reported to be 64% when blood was taken at the time of biopsy, compared with a positive rate of 22% several months after kidney biopsy due to spontaneous or drug-induced remission in some patients. Detecting anti-PLA 2 R at the time of initial diagnosis is recommended, to avoid possible confounding of disease progression and therapy. 2 Also, the effect of immunosuppressive therapy should be taken into account. Moreover, differences in test methodology could contribute to observed discordance in results. Although we observed a statistically similar performance of anti-PLA 2 R via ELISA and via IIF, we note that, in the present study, 3 specimens that tested negative via IIF yielded a positive result via ELISA, and 4 specimens that tested positive via IIF tested negative via ELISA. These inconsistent results probably could be explained by the differences in the antigen-binding matrices utilized in each platform. In ELISA, purified recombinant PLA 2 R antigens are absorbed passively to the plastic matrix, and the reactivity of antibodies is dependent mostly on the number of sufficiently exposed epitopes for binding. In IIF, overexpression of recombinant PLA 2 R in transfected HEK239 cells is applied, and anti-PLA 2 R is probably prone to combine its native cellular domain, which had more native expression of epitopes. Further, specimens with unclear anti-PLA 2 R titer readings are more prone to yield inconsistent results due to the differences in sensitivity and specificity of anti-PLA 2 R testing. When the results of anti-PLA 2 R testing are inconsistent with pathological or clinical indications, clinicians should consider whether this discrepancy is caused by differences of methodologies.
Comparing with ELISA, IIF is a semiquantitative test with less operation steps and shorter incubation time. We can obtain IIF results through the observation of fluorescence under microscope and standard curve is not needed. Determination of anti-PLA 2 R via IIF is widely used by small scale medical laboratories due to its simplicity. Although it has good agreement with ELISA, IIF is limited due to its weak adaptability to high-throughput clinical laboratories.
The superior characteristic of quantitative ELISA is that it provides more-accurate monitoring of changes in anti-PLA 2 R concentration, which is helpful for immunosuppressive therapy monitoring and monitoring of disease progression. 14, 17 Currently, ELISA assay to determine anti-PLA 2 R levels is widely used in clinical practice, due to its advantages.
In summary, our data demonstrate that anti-PLA 2 R levels were significantly higher in pMN compared with sMN; therefore, anti-PLA 2 R levels may serve as an alternative diagnostic biomarker for pMN. Although similar diagnostic performance of anti-PLA 2 R testing via ELISA and IIF was observed statistically, we remind readers that a small portion of specimens showed inconsistent results via 2 immunoassays regarding the differences in antigen-binding matrices utilized in the platforms. 
Figure 2
Results of receiver operating characteristic (ROC) curve analysis of various analyte values, including phospholipase A2 receptor (PLA 2 R), to differentiate primary membranous neuropathy (pMN) from secondary membranous neuropathy (sMN). TP indicates total protein; ELISA, enzyme-linked immunosorbent assay; and IIF, indirect immunofluorescence assay. 
Figure 1
Serum anti-phospholipase A2 receptor (anti-PLA 2 R) titers, as determined via indirect immunofluorescence assay (IIF) and enzyme-linked immunosorbent assay (ELISA).
